Oncology – Urological
RCT | Orteronel for metastatic hormone-sensitive prostate cancer.
8 Jul, 2022 | 11:18h | UTCCommentary: Orteronel Misses Goal in Metastatic Hormone-Sensitive Prostate Cancer – HealthDay
Commentary on Twitter
⛔ SWOG-1216: Orteronel did not improve overall survival for metastatic hormone sensitive #ProstateCancer ➡️ https://t.co/aejFNEb7bM #JCO #PCSM @theNCI @SWOG @neerajaiims @shilpaonc pic.twitter.com/LP5oHQqSIg
— Journal of Clinical Oncology (@JCO_ASCO) May 6, 2022
Consensus Statements | Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in patients with prostate cancer and with respect to [177Lu] Lu-PSMA radioligand therapy.
6 Jul, 2022 | 11:39h | UTCNetwork M-A | High-dose radiotherapy or androgen deprivation therapy as treatment intensification for localized prostate cancer.
6 Jul, 2022 | 11:09h | UTCHigh-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium – European Urology (link to abstract – $ for full-text)
Commentary on Twitter
New In Press: High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortiumhttps://t.co/rZnBjvccNe@AmarUKishan @DrSpratticus et al. pic.twitter.com/uCrg7sRmsS
— European Urology (@EUplatinum) April 25, 2022
RCT | Effect of levofloxacin on the efficacy and adverse events in intravesical Bacillus Calmette-Guerin treatment for bladder cancer.
4 Jul, 2022 | 12:19h | UTCOpinion | Renaming Gleason Score 6 prostate to noncancer: a flawed idea scientifically and for patient care.
30 Jun, 2022 | 10:44h | UTCOriginal Opinion Paper: Low-Grade Prostate Cancer: Time to Stop Calling It Cancer – Journal of Clinical Oncology
Study: Biochemical failure is not a surrogate end point for overall survival in recurrent prostate cancer.
28 Jun, 2022 | 10:32h | UTCBiochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601 – Journal of Clinical Oncology (link to abstract – $ for full-text)
Longitudinal molecular profiling of circulating tumor cells in metastatic renal cell carcinoma.
24 Jun, 2022 | 10:46h | UTCLongitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma – Journal of Clinical Oncology (link to abstract – $ for full-text)
News Release: Non-invasive liquid biopsy tracks cancer treatment success in real time – University of Wisconsin–Madison
Commentary: Longitudinal Liquid Biopsy for Circulating Tumor Cells in Metastatic Renal Cell Carcinoma – The ASCO Post
Commentary on Twitter
💡 Longitudinal analysis of circulating tumor cells from metastatic #RenalCellCarcinoma provides insight into changes in both tumor burden & #MolecularProfile of tumor cells in response to treatment. #JCO #kcsm @joshlangmd https://t.co/fPU8PepHJR pic.twitter.com/cKPvXiPB0W
— Journal of Clinical Oncology (@JCO_ASCO) June 10, 2022
ASCO Guideline: Management of metastatic clear cell renal cell carcinoma.
22 Jun, 2022 | 11:30h | UTC
Long-term follow-up of a RCT: Nivolumab plus cabozantinib vs. sunitinib in first-line treatment for advanced renal cell carcinoma.
22 Jun, 2022 | 10:48h | UTCNivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Original Study: Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma – New England Journal of Medicine
Commentary from the author on Twitter (thread – click for more)
1/ CheckMate-9ER extended f/u (media f/u=32.9mo) results out in @TheLancetOncol: preplanned final OS analysis, updated PFS, OR & safety of Cabo/Nivo vs. Sun in 1L RCC. Also includes prespecified & post-hoc subgroup analyses. https://t.co/OJduO7Q2ar@OncoAlert @DanaFarber_GU pic.twitter.com/0EQN5gWu5I
— Toni Choueiri, MD (@DrChoueiri) June 8, 2022
Consensus definition and management recommendations: intermediate-risk non–muscle-invasive bladder cancer.
21 Jun, 2022 | 10:52h | UTCIntermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group – European Urology – Oncology (if the link is paywalled, try this one)
Commentary from the author on Twitter
Intermediate-risk NMIBC: Updated Consensus Definition & Management Recs from IBCG (International Bladder Cancer Group)
Full text: https://t.co/QaqGqRN3AE @drtanws @garysteinbergmd @DrShariat @UrogerliMD @MRoupret @spsutkaMD @joanfundi @MarekBabjuk @SWilliams_MD #bladdercancer pic.twitter.com/XQ1sdhqXPZ— Ashish M. Kamat, MD, MBBS (@UroDocAsh) June 17, 2022
RCT: Active surveillance plus Enzalutamide monotherapy vs. active surveillance alone in patients with low-risk or intermediate-risk localized prostate cancer.
21 Jun, 2022 | 10:33h | UTCInvited Commentary: To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer—Weighing the Evidence – JAMA Oncology (free for a limited period)
Video criticizing the article: ENACT trial | A Study That Makes Pharma Rich and Patients’ Poor | I break it down – by Vinay Prasad
Commentaries on Twitter
55% fatigue and 36% gynecomastia. In AS patients.
Why do we keep trying to escalate when the data CLEARLY say we should continue to de-escalate? https://t.co/LY1kD0jN65
— Chris Barbieri (@Chris_Barbieri1) June 17, 2022
The phase 2, open-label ENACT trial compares the efficacy & safety of enzalutamide monotherapy vs active surveillance in patients with low- or intermediate-risk localized #prostatecancer. https://t.co/q9FrL14em1 #PCSM #GUCSM
— JAMA Oncology (@JAMAOnc) June 16, 2022
Single-arm phase 2b study: MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer.
20 Jun, 2022 | 00:56h | UTCMRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
In single-arm phase IIb trial of MRI-guided focused ultrasound therapy in 101 men with primary, group 2‒3 intermediate-risk untreated prostate adenocarcinomas, 88% had no evidence of group ≥2 prostate cancer in the treated area at 2 years: https://t.co/xLpqfFm8Ds #PCSM
— NatureRevClinOncol (@NatRevClinOncol) June 16, 2022
Long-term results of RCT: Radiotherapy to the prostate for men with metastatic prostate cancer.
10 Jun, 2022 | 11:10h | UTC
New study associates intake of dairy milk with greater risk of prostate cancer.
10 Jun, 2022 | 10:50h | UTCOriginal Study: Dairy foods, calcium intakes, and risk of incident prostate cancer in Adventist Health Study–2 – American Journal of Clinical Nutrition (link to abstract – $ for full-text)
RCT: Abiraterone and Olaparib for metastatic castration-resistant prostate cancer.
9 Jun, 2022 | 10:21h | UTCAbiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer – NEJM Evidence
Commentary on Twitter
Combination treatment with abiraterone and olaparib increased progression-free survival regardless of homologous recombination repair gene mutation status in patients with metastatic castration-resistant #ProstateCancer treated in the first-line setting. https://t.co/CAUDF2ZErG pic.twitter.com/YARZa8AUXJ
— NEJM Evidence (@NEJMEvidence) June 3, 2022
Circulating tumor DNA as a biomarker in patients with stage III and IV Wilms tumor.
8 Jun, 2022 | 10:43h | UTCCommentary: Analysis of Circulating Tumor DNA as a Biomarker in Stage III and IV Wilms Tumor – The ASCO Post
Nationwide cohort study: Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in nonmetastatic prostate cancer.
3 Jun, 2022 | 11:10h | UTCCommentary: ADT for Prostate Cancer: What’s the Risk on the Heart? – Medscape (free registration required)
Clinical practice guidelines for penile cancer.
2 Jun, 2022 | 10:57h | UTC
Cohort Study: Taking 5-ARIs for BPH is not associated with increased mortality in prostate cancer.
1 Jun, 2022 | 10:59h | UTCNews Release: Taking 5-ARIs for BPH is not associated with increased mortality in prostate cancer – Karolinska Institute
Original Study: Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality – JAMA Oncology (link to abstract – $ for full-text)
Authors Interview: Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality – JAMA
Commentary: Large study finds no increased risk for prostate cancer death with 5-ARI use – medwire News
Commentary on Twitter
This large population-based cohort study found that men treated with 5α-reductase inhibitors had no increased risk of dying from #prostatecancer, on the contrary indicating a decreased risk with longer treatment duration. https://t.co/y8HlpthNI9 #PCSM #GUCSM
— JAMA Oncology (@JAMAOnc) May 19, 2022
10-yr follow-up of a phase 3 RCT: chemoradiotherapy in muscle-invasive bladder cancer.
30 May, 2022 | 10:52h | UTC
Commentary on Twitter
Chemoradiotherapy in MIBC: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trialhttps://t.co/x8EFIoiqla@Prof_Nick_James @ProfSyedHussain @robert_huddart @NPortaStat
"Long-term findings confirm the benefit of adding 5-FU and MMC to RT for MIBC" pic.twitter.com/bKWSWhwemB
— European Urology (@EUplatinum) May 19, 2022
Position Paper: Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer.
26 May, 2022 | 10:42h | UTC
Cohort Study: Risk of venous thromboembolism in men with prostate cancer compared with men in the general population.
25 May, 2022 | 11:01h | UTCNews Release: Men with prostate cancer have a higher risk of serious blood clots – BMJ
Commentary on Twitter
Men with prostate cancer have a 50% higher risk of developing venous thrombosis during the 5 years following their cancer diagnosishttps://t.co/RrYAB5lSrb pic.twitter.com/VGMI7GILgE
— K Pavithran (@drkpavithran) May 24, 2022
Under a http://creativecommons.org/licenses/by-nc/4.0/ license
RCT: The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy.
18 May, 2022 | 10:49h | UTCThe addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial – The Lancet (link to abstract – $ for full-text)
M-A: Comparison of radiofrequency ablation vs. cryoablation For T1 renal tumors.
18 May, 2022 | 10:25h | UTC
Cohort Study: Survival outcomes associated with cytoreductive nephrectomy in patients with metastatic clear cell renal cell carcinoma.
17 May, 2022 | 10:41h | UTC
Commentary on Twitter
In this cohort study, instrumental variable analysis did not find a survival advantage associated with cytoreductive nephrectomy for patients with metastatic clear cell renal cell carcinoma. https://t.co/iljbmtZW4f
— JAMA Network Open (@JAMANetworkOpen) May 16, 2022